Full-Time

Chronic Care Specialty Sales Representative

Multiple Teams

Posted on 10/4/2025

Deadline 10/10/25
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$77.7k - $163.9k/yr

+ Annual Bonus + Long-term Incentive

No H1B Sponsorship

Daytona Beach, FL, USA + 4 more

More locations: Macon, GA, USA | Columbus, GA, USA | Jacksonville, FL, USA | St. Petersburg, FL, USA

In Person

Candidates must reside in the territory or within 25 miles of the workload center for designated metro territories, or within 75 miles for non-metro territories; if outside these distances, candidates must be willing to relocate at their own expense.

Category
Sales & Account Management (1)
Required Skills
Sales
Marketing
Data Analysis
Requirements
  • Bachelor’s degree (BA/BS), or High school diploma or equivalent with 0-3 years of relevant work experience, which may include professional sales, marketing, military service, or roles within healthcare or scientific fields such as pharmaceuticals, biotechnology, or medical devices.
  • Able to analyze complex data and leverage insights to develop strategic sales plans.
  • Comfortable using digital tools and platforms to engage with healthcare professionals.
  • Flexible and adaptable to changing market conditions and customer expectations.
  • Proven track record of success in both educational and professional environments, demonstrating strong interpersonal, analytical, and communication skills.
  • Works well both independently, with excellent organizational and time management skills, and collaboratively within team-oriented settings.
  • Valid driver’s license.
  • Demonstrate strong ability at building and maintaining customer relationships by understanding and addressing their needs effectively.
  • Reside in the territory or within 25 miles of the workload center for designated metro territories, or within 75 miles for non‑metro territories; if outside these distances, candidates must be willing to relocate at their own expense.
Responsibilities
  • Develop and execute a territory-level business plan in alignment with company policies, standards, and ethics.
  • Maintain current product knowledge and certifications for the company’s portfolio.
  • Conduct balanced and compliant product sales discussions with health care providers and business professionals to align customer needs with company products according to product labeling.
  • Provide management with regular updates on customer needs, marketplace dynamics, and progress toward quality goals.
  • Be knowledgeable on headquarter approved information regarding approved company products, disease, and marketplace.
  • Monitor business performance against objectives using company tools to support effective planning and sales impact.
Desired Qualifications
  • Background in sales, account management, consultative roles, or customer service.
  • Experience analyzing metrics to evaluate progress toward goals.
  • Minimum of 3 years of relevant sales experience.
  • Cardiovascular sales experience with established relationships with cardiologists and endocrinologists.
  • Experience launching products and succeeding in competitive markets.
  • Ability to simplify complex information and convey technical details clearly.
  • Proficient in using advanced analytics to generate customer insights and drive sales.
  • Comfortable leveraging multi-channel tools and technology to expand sales reach and impact.
  • Demonstrates a proactive learning approach and an agile growth mindset.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Multiple 2026 approvals and collaborations expand the pipeline beyond Keytruda.
  • China biotech partnerships create repeatable access to early oncology and autoimmune assets.
  • Cost cuts targeting $3 billion by 2027 can fund new launches.

What critics are saying

  • Keytruda loses patent protection in 2028, pressuring Merck's largest cash generator.
  • Gardasil faces 2028 patent loss, compounding post-Keytruda revenue decline.
  • Animal Health securities litigation could force disclosure scrutiny, settlements, and valuation damage.

What makes Merck unique

  • Merck combines blockbuster oncology, vaccines, infectious diseases, and animal health businesses.
  • Its Keytruda franchise anchors R&D, partnerships, and late-stage combination strategies.
  • Merck Life Science adds biologics testing and manufacturing-adjacent services beyond pharmaceuticals.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Merck who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

9%

2 year growth

9%
Merck
May 15th, 2026
Merck and City Cancer Challenge expand global partnership to strengthen women's cancer care.

Merck and City Cancer Challenge expand global partnership to strengthen women's cancer care. This initiative aims to reach more than 300,000 women living with cancer around the world by 2030 May 15, 2026 Millions of women around the world are diagnosed with cancer every year. Breast, cervical, ovarian and endometrial cancers accounted for nearly one in five new cancer cases and 1.3 million deaths globally in 2022. Research suggests that some of the deaths from these cancers may be avoided through a combination of effective public health policies, earlier detection and timely medical care. At Merck, we recognize the importance of working with organizations committed to closing gaps in care for people who need it most. That's why we're expanding our partnership with City Cancer Challenge (C/Can) with a five-year, $10 million investment to improve cancer care for women in 15 cities around the world through community-led collaboration. What is City Cancer Challenge? C/Can is an international non-profit organization that brings together public and private partners at the city level to design, plan and implement practical solutions to help address gaps in cancer care. The organization leverages the unique value of cities as enablers in a health system's response to cancer. C/Can works with municipal leaders, health authorities, clinicians and patient groups in cities across low- and middle-income countries (LMICs), reaching over 764,000 patients with opportunities for improved quality of care. Supporting the thriving Cities, Healthy Women initiative. Merck has been a partner of C/Can since the organization's founding in 2019. Building on this work, we're investing in its new "Thriving Cities, Healthy Women" initiative to help close gaps in access to cancer screening and care for women in LMICs across Africa, Latin America, Southeast Asia and Eastern Europe. "Too many women are diagnosed too late, receive care too late or never receive care at all. That's not inevitable - it's fixable. Prioritizing women and health does not only benefit women and their families, it can also be a powerful lever for stronger health systems, economic resilience and social progress." * Isabel Mestres CEO, City Cancer Challenge By 2030, the partnership aims to: Reach more than 300,000 women with cancer through improved access to care Train more than 2,000 health professionals through capacity building and mentorship Benefit more than 11 million women through influencing policy, replication and scale-up of patient initiatives "People should be able to access timely cancer care - no matter where they live. By partnering with City Cancer Challenge, we're working city by city to strengthen local systems so more women can be diagnosed earlier and get the care they need close to home." * Kalahn Taylor-Clark, Ph.D., MPH Vice president and head of social impact and sustainability, Merck How we're closing the cancer care gap. Women often navigate cancer with unique responsibilities and pressures. Socioeconomic barriers, geography, caregiving demands and other factors can stand in the way of early detection and timely diagnosis. In many settings, women experience delayed referrals, unclear diagnostic pathways and long waits to access care - all of which may lead to worse outcomes. "By investing in the health of women, we invest in stronger families, resilient communities and more productive societies." * Jenelle Krishnamoorthy, Ph.D. Senior vice president and head of global policy and public affairs, Merck Through our partnership with C/Can, participating cities will work toward measurable, sustainable improvements in women's cancer care to: * Expand access to screening, as early detection may impact outcomes * Reduce the time from suspicion of cancer to confirmed diagnosis or rule-out * Increase the number of women initiating cancer care plans soon after diagnosis Discover more stories

Pharma Focus Asia
May 12th, 2026
Erasca Enters into Collaboration with Merck to Evaluate ERAS-0015 with KEYTRUDA in RAS-Mutant Solid Tumours.

Erasca Enters into Collaboration with Merck to Evaluate ERAS-0015 with KEYTRUDA in RAS-Mutant Solid Tumours. Tuesday, May 12, 2026 Erasca has entered into a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015 in combination with KEYTRUDA for patients with RAS-mutant solid tumours. The agreement will support the AURORAS-1 clinical proof-of-concept study, which is assessing the investigational pan-RAS molecular glue ERAS-0015 together with pembrolizumab, Merck's anti-PD-1 therapy. Erasca is sponsoring the study, while Merck will provide pembrolizumab at no cost. The companies are exploring the potential of the combination therapy to improve treatment outcomes in cancers driven by RAS mutations. RAS mutations are known to activate the RAS/MAPK pathway and contribute to an immunosuppressive tumour environment. Preclinical findings suggest that ERAS-0015 may help enhance the effects of PD-1 blockade by reducing immunosuppression and supporting stronger and longer-lasting tumour responses. Globally, around 2.7 million patients are diagnosed each year with RAS-mutant tumours. Limited treatment options targeting multiple RAS mutations and the development of resistance mechanisms remain major challenges in treating these cancers. ERAS-0015 is an investigational oral therapy designed to inhibit RAS signalling across a broad range of mutations. The therapy is currently being evaluated in the Phase 1 AURORAS-1 trial in patients with RAS-mutant solid tumours. Early dose-escalation results from the study showed favourable safety and tolerability, linear pharmacokinetics, and confirmed as well as unconfirmed partial responses in patients across different tumour types and RAS mutations. Responses were observed at doses as low as 8 mg once daily. The therapy is also designed to address resistance associated with mutant-selective inhibitors through inhibition of RAS wildtype variants. In addition, ERAS-0015 demonstrated favourable absorption, distribution, metabolism, excretion, and pharmacokinetic properties in preclinical animal studies.

BJMO
May 8th, 2026
Hybrid therapy breaks through: drugs and apps used together against rare tumors.

Hybrid therapy breaks through: drugs and apps used together against rare tumors. Pharmaceuticals Remepy and Merck explore hybrid treatment approach for rare tumors, combining drugs with AI-driven digital protocols via an app to enhance effectiveness. This innovation specifically targets cancers with unmet medical needs, where behavioral support, physiotherapy, and symptom monitoring can reinforce pharmacological effects. AI-driven app The Remepy app is a personalized digital therapeutic platform delivering evidence-based interventions via a mobile application, designed to stimulate neuroplasticity, balance the immune system, and promote behavioral change. It combines multisensory stimulation (visual, auditory, and tactile) with protocols such as cognitive behavioral therapy, mindfulness, psychoeducation, sensory modulation, and physiotherapy exercises. The app simultaneously activates multiple mechanisms: it reduces systemic inflammation through stress reduction, enhances brain plasticity via enriched multisensory environments, triggers the reward system to improve therapy adherence, and improves motor control with exercises for speech, balance, and fine motor skills. For emotional and cognitive support, it provides attention training, emotion regulation, and sleep interventions - all AI-driven and personalized in real-time through patient data and smart notifications. RMPY-008 study The Remepy-conducted RMPY-008 study, a randomized controlled trial in 103 adults with subjective cognitive decline, tested the app over three weeks. The design included randomization to intervention or control, with pre- and post-measurements of inflammatory biomarkers, psychological scales, and fMRI for brain connectivity. Results showed significant reductions in pro-inflammatory cytokines (TNF-α, IL-17, IL-23, IL-12, IFN-γ, MCP-1), improved mood and resilience, and enhanced fronto-limbic connectivity, with 94% therapy adherence. Hybrid therapy collaboration The collaboration focuses on Merck's rare tumor portfolio, where hybrid therapies could reduce toxicity and improve outcomes through personalized remote care. Examples include guided physiotherapy, pain management, and medication tracking - ideal for heterogeneous diseases with high care needs. This approach leverages recent FDA frameworks for combined drug-software products, with potential for label expansions. References * Remepy press release * Catalogna, M., Saporta, N., Nathansohn-Levi, B. et al. Mobile application leads to psychological improvement and correlated neuroimmune function change in subjective cognitive decline. npj Digit. Med. 8, 359 (2025). https://doi.org/10.1038/s41746-025-01765-1

Castlefield
Apr 27th, 2026
Engagement update with Merck & co on animal testing and packaging.

Engagement update with Merck & co on animal testing and packaging. By Ffion Spencer * Share * April 27/04/2026, 12:00 AM As part of its ongoing efforts to improve performance across key environmental, social, transparency and governance (E.S.T.) metrics, Castlefield Partners Limited recently engaged with US pharmaceutical company Merck & co., held in the castlefield thoughtful World Equity Fund, to discuss its approach to animal testing, the use of animal-derived ingredients, and packaging practices. At a recent External Advisory Committee meeting, the committee highlighted increasing numbers of animals being used in animal testing across the pharmaceutical sector. Around the same time, Castlefield Partners Limited also received a client query relating to the use of animal derived ingredients in pharmaceutical products. This engagement therefore focused on three material topics for the pharmaceutical industry: animal testing, the use of animal derived ingredients in products, and plastic use. In its initial response, Merck explained that it makes extensive use of non animal research methods, including in vitro techniques, computer modelling and advanced imaging, prior to or instead of animal studies. The company shared that approximately 96% of its research animals are rodents and confirmed that it maintains detailed records on animal use across species, purpose and site, including research carried out by third party organisations on Merck's behalf. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. While this response suggests a baseline level of governance and oversight, Castlefield Partners Limited believe there is scope for further progress. Castlefield Partners Limited has followed up and are awaiting further written responses.Castlefield Partners Limited note that some peers, including French pharmaceutical company Sanofi, which is also held in the World Equity Fund, publish the total number of animals used for scientific research on an annual basis. As Merck has confirmed that it maintains this data internally, Castlefield Partners Limited has encouraged greater transparency through public disclosure. Castlefield Partners Limited also encouraged the company to consider setting reduction targets on this topic. On animal derived ingredients, Merck highlighted the use of specialised tools to identify potential non animal alternatives, indicating consideration of reduction and substitution where scientifically feasible. On plastics, the company shared that it has developed a long term roadmap aimed at reducing the environmental impact of its packaging, suggesting an acknowledgement of plastics as a material environmental issue within its operations. Overall, while Merck provided high level information across all three topics, the most detailed discussion related to animal testing, reflecting its materiality to the sector. Outcome: Its engagement confirmed that Merck has a level of baseline governance on these topics. However, further engagement with the company is required, particularly in relation to transparency and disclosure on the number of animals used in scientific testing. Information is accurate as at 20.04.2026. Opinions constitute the fund manager's judgement as of this date and are subject to change without warning. The officers, employees and agents of CIP may have positions in any securities mentioned herein. This material may not be distributed, published or reproduced in whole or in part. With investment, capital is at risk.

Yahoo Finance
Apr 14th, 2026
Merck keeps Keytruda cancer drug prices high as single dose reaches $163K

Merck's cancer drug Keytruda has become a pricing flashpoint in US healthcare, with a single 400mg dose billed at $162,567 at a California clinic, despite Merck's list price of $24,000. The drug generated $31.7 billion in worldwide sales in 2025, representing nearly half of Merck's revenue. A joint investigation by the International Consortium of Investigative Journalists and USA TODAY found Merck employs multiple tactics to maintain high prices, including building patent walls against generic competition, lobbying against Medicare price negotiations, and maintaining higher dosing despite studies suggesting weight-based dosing would be effective and cheaper. Whilst Merck CEO Robert Davis pledged support for President Trump's drug pricing initiatives in December, he made no commitments regarding Keytruda. Merck attributes US price inflation to pharmacy benefit managers and insurers who add fees and rebates.

INACTIVE